This article has been updated to clarify that the prevalence of FGFR2b-positive, HER2-negative gastric cancers is an observation outside of the FIGHT trial.
NEW YORK – Five Prime Therapeutics on Tuesday announced topline results from its Phase II trial of bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer that overexpresses FGFR2b.